Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Triple-positive profile may flag adverse prostate cancer pathology
A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.
Triple-positive profile may flag adverse prostate cancer pathology
Overview
A combination of prostate-specific antigen density, multiparametric MRI, and PSMA PET/CT findings may identify a subgroup of prostate cancer patients at risk for adverse pathology. In a study of 413 patients, those meeting all three criteria had a 100% positive predictive value for adverse pathology.
Background
Prostate cancer remains a significant health concern, being the second leading cause of cancer-related deaths among men in the United States. Accurate identification of patients at risk for aggressive disease is crucial for guiding treatment decisions. The integration of advanced imaging techniques with clinical parameters may enhance diagnostic accuracy and inform biopsy strategies.
Data Highlights
Parameter
Adverse Pathology Rate
PSAD ≤ 0.15
48%
PSAD > 0.15
72%
PI-RADS 3 or lower
45%
PI-RADS 4
52%
PI-RADS 5
80%
PRIMARY 1 to 4
55%
PRIMARY 5
85%
Key Findings
60% of patients had adverse pathology at radical prostatectomy.
Adverse pathology rates increased with higher PSAD and PI-RADS scores.
Age, PSAD, PI-RADS 5, and PRIMARY 5 were independently associated with adverse pathology.
The combined model of clinical and imaging predictors showed greater discrimination for adverse pathology than individual parameters.
All patients with PSAD > 0.15, PI-RADS 5, and PRIMARY 5 had adverse pathology.
The triple-positive profile had 100% specificity and positive predictive value, but low sensitivity (9%).
Clinical Implications
The findings indicate that combining PSAD, mpMRI, and PSMA PET/CT may help identify patients at risk for adverse pathology.
Conclusion
The study highlights the potential of a triple-positive profile in identifying patients with adverse prostate cancer pathology.
A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
